Abstract
Tobacco-associated nitrosamines are known carcinogens causing DNA damage in epithelial cells of the head and neck. A matched case-control study was performed to evaluate the sensitivity of patients with squamous cell cancer (SCC) of the oropharynx, and controls to tobacco-associated nitrosamines. Quantitative DNA repair was evaluated following a period of 15 and 30 min. Fresh biopsies from 100 male donors of macroscopically healthy oropharyngeal cells and lymphocytes (50 SCC patients and 50 controls) were incubated with N-nitrosodiethylamine (NDEA), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) or N-nitrosonornicotine (NNN). DNA damage in epithelial cells and lymphocytes was assessed using the comet assay. Following incubation with NDEA, cells underwent a period of DNA repair. All of the nitrosamines caused equivalent genotoxic damage in mucosal cells and lymphocytes of the two groups. Lymphocyte DNA repair capacity in the control group (26.8 and 37.1% after 15 and 30 min) was comparable to the tumor group (23.6 and 40.6%). However, epithelial cell DNA repair capacity of carcinoma patients was significantly reduced to 17.1% (15 min) and 23% (30 min) compared to the DNA repair of the control group (36.2%, 15 min and 46.0%, 30 min). Mutagen sensitivity was comparable in patients and controls. Thus, reduced epithelial cell DNA repair capacity of tumor patients is a possible endogenous risk factor for the development of head and neck squamous cell cancer.
Keywords: mutagen sensitivity, DNA repair, lymphocytes, oropharynx, comet assay, repair capacity
Introduction
The incidence and mortality of upper aerodigestive tract carcinomas remain persistently high regardless of diagnostic and therapeutic improvements (1). Exogenous risk factors, such as tobacco smoke and alcohol consumption, are acknowledged causes of head and neck cancer (2). However, only a fraction of smokers are likely to develop head and neck cancer during their lifetime. Therefore, the importance of endogenous risk factors is of growing interest in the multifactorial genesis of head and neck squamous cell cancer (HNSCC). Individual mutagen sensitivity and DNA repair capacity are likely to be candidates affecting an individual’s susceptibility to cancer (3).
Tobacco-associated nitrosamines, such as N-nitrosonor-nicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-nitrosodiethylamine (NDEA) are known to be involved in the carcinogenesis of HNSCC. NNN is classified as a class 1 carcinogen by the IARC (4). This nicotine derivative is found in tobacco smoke, with 200–3000 ng in cigarettes without filters (5). NNK is classified as class 1 by the IARC as well, although it was found to be a stronger carcinogen in animal testing (4,6). NDEA is a class 2b carcinogen, and its effect is local and systemic, with 20–70 ng in the smoke of cigarettes without filters (5,7). The nitrosamines are metabolized in the cells by cytochrome P-450-dependent hydroxylases into an alkylating agent, which may induce DNA strand breaks and cause incomplete base excision repair. Furthermore, NNN and NNK have genotoxic effects through the formation of oxygen radicals (8).
As in most tumors, the regulatory steps are altered during multi-step tumor development (9). Regular cell survival is dependent on a well-balanced relationship between ongoing DNA damage and repair (10,11). The importance of DNA repair capacity (DRC) on cancer susceptibility was previously described in lung cancer patients (12). The ability to detect and repair DNA damage caused by environmental toxicants or endogenous processes is assumed to be a significant defense mechanism against the development of head and neck cancer.
Most studies on DRC are based on lymphocytes as the surrogate cell type (13,14). However, environmental carcinogens primarily damage the mucosa of the upper aerodigestive tract, with epithelial cells being the first target for head and neck carcinogenesis. Due to previous findings showing poor correlation between genotoxic sensitivity of peripheral blood lymphocytes and upper aerodigestive tract epithelia, we included the two cell types in our investigations to further differentiate systemic and local effects (15).
The aim of the study was to evaluate mutagen sensitivity and DRC in human lymphocytes and epithelial cells of the oropharynx of patients with and without squamous cell carcinoma (SCC) of the oropharynx. DNA fragmentation following nitrosamine-induced damage, as well as DNA repair capacities in 15 and 30 min, were measured using the alkaline single cell microgel electrophoresis (comet) assay. DRC following nitrosamine-induced DNA damage was presented within matched patient groups using parameters such as age, gender, tobacco and alcohol consumption.
Materials and methods
Biopsies and blood samples
Macroscopically healthy epithelial biopsies were obtained from oropharyngeal resection specimens of SCC patients and from surgery of the oropharynx in patients without SCC. For the evaluation of DNA damage and repair using nitrosamines, SCC patients (n=50, all male, mean age 51.3 years; range 35–62) were matched to control patients (n=50, all male, average age 50.4 years; range 35–62). Only mucosa that had to be resected for surgical reasons were used to avoid additional stress for the patients. Subjects were informed about the experiments and had signed a written consent statement. Tumor patients were first-time cancer patients and did not receive any prior treatment, including radiotherapy or chemotherapy. Control patients underwent tonsillectomy based on the diagnosis of tonsillitis or obstructive sleep apnea syndrome (OSAS). Lymphocytes were isolated by centrifugation of 20 ml heparinized peripheral blood, which was drawn prior to treatment. Patients included in the study were matched by gender, age, alcohol and tobacco consumption. All of the subjects were consumers of alcohol and tobacco smoke. Patient data are shown in Tables I (controls) and II (patients with SCC). The study was approved by the Ethics Commission of the Medical Department, Ludwig-Maximilians-University Munich (No. 221/04).
Table I.
No. | Age | BMI | Diagnosis | Cig/d | Py | Alcohol /d (g) | Occupational hazards |
---|---|---|---|---|---|---|---|
1 | 50 | 27 | Acute tonsillitis | 10 | 30 | 100 | |
2 | 48 | 22 | Sleep apnea | 30 | 23 | 64 | |
3 | 40 | 24 | Chronic tonsillitis | 15 | 20 | 10 | |
4 | 47 | 27 | Acute tonsillitis | 15 | 15 | 25 | |
5 | 50 | 22 | Chronic tonsillitis | 20 | 20 | 20 | |
6 | 42 | 29 | Sleep apnea | 40 | 50 | 10 | |
7 | 46 | 28 | Sleep apnea | 50 | 36 | 125 | Paints, lubricants, varnish |
8 | 54 | 22 | Chronic tonsillitis | 25 | 38 | 25 | Metal dust |
9 | 40 | 25 | Chronic tonsillitis | 5 | 3 | 25 | |
10 | 42 | 27 | Chronic tonsillitis | 20 | 25 | 72 | Chemicals |
11 | 52 | 30 | Chronic tonsillitis | 20 | 10 | 175 | |
12 | 34 | 22 | Chronic tonsillitis | 2 | 1 | 50 | Paints |
13 | 56 | 22 | Chronic tonsillitis | 10 | 10 | 20 | |
14 | 40 | 22 | Chronic tonsillitis | 5 | 2 | 37 | |
15 | 54 | 30 | Chronic tonsillitis | 20 | 80 | 10 | Wood dust |
16 | 42 | 28 | Chronic tonsillitis | 60 | 50 | 20 | |
17 | 54 | 21 | Chronic tonsillitis | 20 | 20 | 15 | |
18 | 51 | 33 | Chronic tonsillitis | 15 | 16 | 45 | Paints |
19 | 48 | 31 | Chronic tonsillitis | 10 | 24 | 10 | |
20 | 54 | 27 | Sleep apnea | 20 | 40 | 125 | Metal dust |
21 | 50 | 27 | Sleep apnea | 40 | 20 | 290 | |
22 | 45 | 28 | Sleep apnea | 30 | 15 | 25 | |
23 | 49 | 29 | Sleep apnea | 5 | 8 | 20 | |
24 | 43 | 25 | Sleep apnea | 12 | 15 | 40 | |
25 | 53 | 19 | Chronic tonsillitis | 10 | 23 | 30 | |
26 | 57 | 28 | Sleep apnea | 5 | 15 | 50 | |
27 | 52 | 22 | Acute tonsillitis | 12 | 15 | 30 | |
28 | 54 | 20 | Acute tonsillitis | 20 | 34 | 175 | |
29 | 53 | 26 | Chronic tonsillitis | 5 | 7 | 60 | Wood dust, glue |
30 | 46 | 25 | Chronic tonsillitis | 12 | 20 | 65 | |
31 | 36 | 25 | Acute tonsillitis | 30 | 21 | 4 | Solvents |
32 | 51 | 24 | Chronic tonsillitis | 10 | 15 | 15 | |
33 | 44 | 31 | Sleep apnea | 20 | 13 | 30 | |
34 | 44 | 28 | Sleep apnea | 15 | 18 | 40 | |
35 | 50 | 31 | Acute tonsillitis | 10 | 12 | 25 | |
36 | 51 | 24 | Sleep apnea | 20 | 35 | 12,5 | |
37 | 57 | 28 | Chronic tonsillitis | 2 | 3 | 69 | Chalk dust |
38 | 53 | 27 | Chronic tonsillitis | 20 | 18 | 120 | |
39 | 61 | 27 | Sleep apnea | 30 | 40 | 30 | |
40 | 45 | 27 | Sleep apnea | 20 | 5 | 25 | |
41 | 47 | 32 | Sleep apnea | 25 | 26 | 50 | |
42 | 43 | 23 | Chronic tonsillitis | 20 | 18 | 10 | |
43 | 61 | 33 | Papilloma | 60 | 80 | 100 | Chemicals |
44 | 63 | 28 | Chronic tonsillitis | 25 | 50 | 45 | |
45 | 63 | 27 | Chronic tonsillitis | 40 | 60 | 50 | Wood dust |
46 | 61 | 27 | Chronic tonsillitis | 25 | 53 | 250 | |
47 | 61 | 31 | Sleep apnea | 50 | 27 | 66 | Paints |
48 | 60 | 26 | Sleep apnea | 20 | 40 | 40 | |
49 | 61 | 28 | Sleep apnea | 30 | 25 | 50 | |
50 | 62 | 30 | Chronic tonsillitis | 15 | 30 | 25 |
BMI, body mass index; cig/d, cigarettes per day; py, pack years; alcohol/d (g), alcohol per day in grams.
Table II.
No. | Age | BMI | Diagnosis | TNM | Grading | Cig/d | py | Alcohol/d (g) | Occupational hazards |
---|---|---|---|---|---|---|---|---|---|
1 | 50 | 25 | Oropharynx carcinoma | pT4 pN3 cM0 | G3 | 50 | 75 | 240 | |
2 | 50 | 32 | Oropharynx carcinoma | pT2 pN3 cM0 | G2 | 50 | 120 | 900 | |
3 | 40 | 22 | Oropharynx carcinoma | pT3 pN2a cMx | G3 | 20 | 13 | 175 | |
4 | 47 | 24 | Oropharynx carcinoma | pT2 pN2b cM0 | G2 | 25 | 40 | 100 | |
5 | 53 | 24 | Oropharynx carcinoma | pT2 pT1 cM0 | G3 | 30 | 50 | 125 | Kerosene |
6 | 46 | 28 | Oropharynx carcinoma | pT1 pN1 cM0 | G3 | 40 | 45 | 50 | Wood dust |
7 | 48 | 23 | Uvula carcinoma | pT3 pN2b cM0 | G3 | 20 | 35 | 100 | |
8 | 57 | 25 | Oropharynx carcinoma | pT4 pN0 cM0 | G3 | 35 | 20 | 205 | Polyvinylchloride |
9 | 44 | 19 | Base of tongue carcinoma | cT4 cN0 cM0 | G1 | 100 | 125 | 200 | |
10 | 47 | 23 | Oropharynx carcinoma | pT3 pN1 cM0 | G3 | 20 | 30 | 150 | |
11 | 48 | 31 | Tonsillar carcinoma | pT2 pN3 cM0 | G2 | 30 | 48 | 300 | Bitumen |
12 | 35 | 22 | Oropharynx carcinoma | cT4 cN2a cMx | G1 | 50 | 40 | 250 | |
13 | 56 | 19 | Oropharynx carcinoma | pT3 cN2c cM0 | G2 | 60 | 60 | 220 | Metal dust |
14 | 44 | 20 | Oropharynx carcinoma | pT4 cN2a cM0 | G3 | 10 | 5 | 10 | |
15 | 56 | 27 | Oropharynx carcinoma | pT4 cN2c cM0 | G3 | 30 | 25 | 100 | |
16 | 47 | 19 | Base of tongue carcinoma | pT4 pN1 cM0 | G3 | 20 | 20 | 900 | |
17 | 56 | 23 | Tonsillar carcinoma | pT2 pN3 cM0 | G3 | 20 | 80 | 60 | Polyvinylchloride |
18 | 54 | 19 | Oropharynx carcinoma | pT3 pN2b cM0 | G2 | 12 | 20 | 160 | Chemicals |
19 | 50 | 27 | Base of tongue carcinoma | pT1 pN1 cM0 | G1 | 20 | 34 | 123 | |
20 | 54 | 23 | Tonsillar carcinoma | pT2 pN2b cM0 | G2 | 30 | 55 | 200 | Oils |
21 | 52 | 24 | Tonsillar carcinoma | pt1 pN2b cM0 | G3 | 30 | 40 | 144 | |
22 | 46 | 22 | Vallecula carcinoma | pT2 pN0 cM0 | G3 | 20 | 63 | 375 | Paints |
23 | 50 | 29 | Oropharynx carcinoma | pT2 Pn0 cMx | G2 | 25 | 23 | 100 | |
24 | 43 | 24 | Tonsillar carcinoma | pT3 pN1 cM0 | G2 | 25 | 15 | 205 | |
25 | 55 | 25 | Oropharynx carcinoma | pT3 pN1 cM0 | G3 | 4 | 5 | 50 | |
26 | 56 | 25 | Tonsillar carcinoma | pT3 pN2b cM0 | G3 | 30 | 72 | 63 | Solvents |
27 | 52 | 32 | Tonsillar carcinoma | pT2 pN2b cM0 | G2 | 30 | 25 | 8 | |
28 | 55 | 22 | Oropharynx carcinoma | pT2 pN1 cMx | G3 | 40 | 60 | 40 | |
29 | 53 | 18 | Oropharynx carcinoma | pT4 pN3 cM0 | G3 | 10 | 8 | 30 | |
30 | 46 | 25 | Oropharynx carcinoma | pT1 pN3 cM0 | G1 | 15 | 12 | 300 | |
31 | 42 | 24 | Oropharynx carcinoma | pT1 pN2b cM0 | G1 | 20 | 20 | 1000 | |
32 | 51 | 24 | Tonsillar carcinoma | pT2 pN1 cM0 | G3 | 20 | 25 | 400 | |
33 | 47 | 26 | Uvula carcinoma | pT3 pN1 cM0 | G1 | 30 | 15 | 90 | |
34 | 42 | 27 | Vallecula carcinoma | pT2 pN0 cM0 | G2 | 15 | 15 | 100 | |
35 | 54 | 21 | Oropharynx carcinoma | pT4 pN2c cM0 | G3 | 50 | 80 | 100 | |
36 | 49 | 20 | Oropharynx carcinoma | pT1 pN0 cM0 | G1 | 20 | 30 | 125 | Metal dust |
37 | 55 | 24 | Tonsillar carcinoma | pT3 pN2b cM0 | G2 | 35 | 60 | 80 | |
38 | 53 | 27 | Oropharynx carcinoma | pT4 pN2a cM0 | G2 | 20 | 20 | 80 | |
39 | 61 | 29 | Uvula carcinoma | pT2 pN0 cM0 | G2 | 40 | 60 | 100 | Paints |
40 | 42 | 21 | Tonsillar carcinoma | pZ3 pN2a cM0 | G2 | 40 | 20 | 100 | |
41 | 67 | 25 | Oropharynx carcinoma | pT1 pN1 cMx | G3 | 25 | 35 | 132 | Chemicals |
42 | 43 | 19 | Oropharynx carcinoma | pT2 pN0 cM0 | G3 | 20 | 27 | 250 | Cement dust |
43 | 62 | 20 | Oropharynx carcinoma | pT3 pN2a cM0 | G1 | 15 | 23 | 60 | |
44 | 62 | 31 | Oropharynx carcinoma | pT1 pN2a cM1 | G3 | 20 | 10 | 55 | Paints |
45 | 62 | 20 | Vallecula carcinoma | pT1 pN1 cM1 | G3 | 5 | 12 | 35 | |
46 | 61 | 27 | Tonsillar carcinoma | cT4 cN3 cM1 | G3 | 20 | 23 | 100 | |
47 | 62 | 22 | Base of tongue carcinoma | PT2 cN2c cM0 | G2 | 12 | 13 | 50 | |
48 | 60 | 25 | Base of tongue carcinoma | pT3 pN2b cM0 | G2 | 30 | 40 | 20 | |
49 | 60 | 29 | Oropharynx carcinoma | pT4 pN2b cM0 | G2 | 20 | 10 | 25 | Asbestos |
50 | 62 | 25 | Base of tongue carcinoma | pT2 pN2b cM0 | G1 | 25 | 30 | 40 |
BMI, body mass index; cig/d, cigarettes per day; py, pack years; alcohol/d (g), alcohol per day in grams.
Cell separation
The mucosa samples underwent enzymatic digestion using collagenase P, hyaluronidase (Boehringer, Mannheim, Germany) and protease E Type XIV from Streptomyces griseus (Sigma, Deisenhofen, Germany) for 45 min in a 37°C shaking water bath to gain single cells (16). Lymphocytes derived from heparinized blood samples were separated in equal amounts of Lymphoprep (Nycomed, Oslo, Norway) using density gradient centrifugation (20 min, 2000 U/min, 20°C). Viability and cell count were investigated using trypane blue staining.
Incubation with nitrosamines
Cell aliquots (5×104) of the two cell types were incubated for 60 min with NNN (10 mM, CAS no. 53759-22-0; Merck, Darmstadt, Germany), NNK (10 mM, CAS no. 64091-91-4; Merck) and NDEA (50 mM, CAS. no. 55-18-5, Merck). Dimethyl sulfoxide (DMSO, 166 mM; Merck), a solvent of the nitrosamines, served as a negative control. NDEA, as an exemplary representative of the nitrosamines, was used to induce damage prior to DNA repair. After NDEA was washed from the cells using Joklik medium and centrifugation (24°C, 400 U/min, 5 min), aliquots were resuspended in Joklik medium and underwent a DNA repair period of 15 and 30 min in a shaking water bath at 37°C. Epithelial cells were suspended in Joklik medium, whereas lymphocytes were maintained in PBS (12).
Comet assay
The performance of the comet assay for the two cell types was mainly based on the protocol of Singh et al (17). Special slides were designed for the comet assay with a frosting of 5 mm along the long edges (76×26 mm, Langenbrinck, Emmendingen, Germany), prepared with 85 μl of 0.5% normal melting agarose (Biozym, Hameln, Germany). Following incubation and repair periods, respectively, cell viability was again examined using trypan blue staining. Having obtained viabilities between 90 and 100%, the remaining aliquots were suspended with 75 μl of 0.7% low melting agarose (Biozym) and applied to the prepared slides. Alkaline lysis (10 ml DMSO, 1 ml Triton-X® and 89 ml alkaline lysis buffer) followed for 1 h. The slides were dried and placed into a horizontal gel electrophoresis chamber (Renner, Dannstadt, Germany), and covered with alkaline buffer solution containing NaOH (10 mM) and Na2EDTA (200 mM) with pH 13.2. Following a 20 min DNA unwinding period, the electrophoresis was started with 25 V and 300 mA for 20 min. Following neutralization (0.4 M Tris, pH 7.5, Merck), the cells were stained with 85 μl ethidium bromide (20 μg/ml, Sigma). The slides were covered with cover slips and stored for less than three days in humidified boxes at 5°C.
Digital analysis
The cells were investigated using a DMLB microscope (Leica, Heerbrugg, Switzerland) with an adapted CCD camera (Cohu Inc., San Diego, CA, USA). A total of 40 representative cells were investigated per slide, using two slides for each aliquot tested. For data analysis the median of each subject was used. Cells were counted and analyzed from different spots on the slide to account for variability of the signals. The comets were measured using an image analysis system (Comet++™, Kinetic Imaging, Liverpool, UK). Comet analysis was performed blinded by one examiner to reduce observer-based divergence. To quantify DNA damage, the Olive Tail Moment (OTM: median DNA migration distance × relative amount of DNA in the tail of the comet) was used (18). DNA repair was calculated by comparing the initial damage in each subject in relation to the damage left after 15 and 30 min of repair time.
Statistical analysis
Statistical analysis was performed using SPSS 16.0™. The OTM values of the patients in the two groups were compared (Mann-Whitney U test) as well as tail moments within each group (Wilcoxon test). General acceptance of the level of significance was p≤0.05. Bonferroni correction was used where necessary. Standard box-plots (lower, median and upper quartile) were used to show the results.
Results
The Comet assay was confirmed as being a sensitive method to quantify DNA damage and DRC. DRC was measured after 15 and 30 min (DRC15 and DRC30). The OTM values provided are medians. History data and diagnoses of the patients are shown in Tables I (controls) and II (SCC patients).
DNA damage in lymphocytes of patients without carcinoma and patients with oropharyngeal carcinoma following incubation with nitrosamines is shown in Fig. 1A. While the solvent DMSO as a negative control did not induce any damage in lymphocyte DNA in tumor and control patients (OTM 1.0 vs. 1.2), significant DNA damage was found following incubation with NDEA (OTM 7.3), NNK (OTM 5.8) and NNN (OTM 5.1) in controls. Only OTMs >2 are considered to reflect relevant DNA damage (16). DNA fragmentation in the SCC group was comparable with OTMs 7.4, 6.0 and 5.2 following incubation with NNN (p=0.58), NNK (p=0.48) and NDEA (p=0.67), respectively.
Fig. 1B shows genotoxicity levels of oropharyngeal epithelial cells following incubation with DMSO (negative control) and the nitrosamines NNN, NNK and NDEA. In the control group, OTMs of 1.3 (DMSO), 8.3 (NDEA), 4.7 (NNK) and 3.9 (NNN) were determined. DNA derived from oropharyngeal epithelial cells of cancer patients yielded OTMs of 7.9 (NDEA), 4.8 (NNK) and 4.0 (NNN) following nitrosamine incubation with an OTM of the negative control of 1.3 (DMSO). No significant differences were observed in DNA damage between tumor patients and patients without malignancy [p=0.55 (NDEA), p=0.95 (NNK) and p=0.67 (NNN)].
DNA repair in lymphocytes following NDEA incubation is shown in Fig. 2A. For the controls, DRC15 was 26.8% and DRC30 was 37.1%. The mean DRC15 and DRC30 of cancer patients was 23.6 and 40.5%, respectively. Differences in lymphocyte DNA repair were not observed between the two groups of donors, with p=0.46 (DRC15) and p=0.62 (DRC30).
However, significant differences were found for the DNA repair capacity between cases and controls for DRC30. The results are shown in Fig. 2B. Following DNA damage caused by NDEA, controls reached DRC levels of 36.2% (DRC15) and 46% (DRC30). Cells of SCC patients yielded a DRC15 of 23% and a DRC30 of 17.1%. OTM values following damage and 15-min repair were 7.3 and following a 30-min repair period 7.86, which demonstrates the arrest of repair action in the cells of carcinoma patients after 20% of repaired damage. Statistical evaluation of DNA repair of the two groups resulted in p=0.09 (DRC15) and p≤0.01 (DRC30).
Discussion
Besides laryngeal cancer, oropharyngeal SCC is the most common alcohol- and tobacco-induced head and neck malignancy. Over 90% of all cases are histopathologically classified as SCC (1). In 100 cancer and non-cancer patients, we investigated mutagen sensitivity following exposure to tobacco-associated nitrosamines. Consecutively to NDEA- induced damage, we determined DRC after 15 and 30 min. We applied the alkaline comet assay as an established sensitive method for the detection of DNA damage and repair and as an accepted biomarker model (19). The comet assay is widely used in ecogenotoxicology studies and as a predictor for tumor therapies, such as radiotherapy (20). While it remains the subject of controversy, OTM is the most informative measure in the comet assay (21).
Oropharyngeal epithelium is the first target for ingested and inhaled carcinogens and therefore employed as test material in this study. Lymphocytes, which have been used in numerous other previous studies evaluating DRC with the comet assay, were also utilized (13,14,22,23).
In the present study, no significant differences in lymphocytic or mucosal mutagen sensitivity were determined between cancer and non-cancer patients. Wu et al found mutagen sensitivity to be a marker for the identification of an increased risk of developing premalignant lesions in the head and neck, using lymphocytes exposed to benzo[a]pyrene diol epoxide (BPDE) and bleomycin (24). In our study, following incubation of the mucosal cells of SCC patients and controls with BPDE, OTMs of the initial DNA damage did not significantly differ. Increased lymphocyte sensitivity to bleomycin has also been observed in lung cancer patients and proven to be a potential biomarker for second primary tumor development in the upper aerodigestive tract (14,25). Further support for the impact of mutagen sensitivity on the carcinogenic process results from the findings by Schantz et al. These authors correlated mutagen sensitivity to chromosome 3p losses known to play a key role in the initiation phase of head and neck cancer development (26).
Following incubation of lymphocytes with NDEA, increased mutagen sensitivity was determined in patients suffering from nasopharyngeal carcinoma, whereas no increased sensitivity was observed following exposure to sodium dichromate and nickel sulphate (27). This may be due to different patient groups and diversity of cells compared to the present study. Investigations on mucosa of head and neck cancer patients indicated increased levels of mutagen sensitivity for SCC patients (16). Studies using the comet assay revealed significantly higher DNA damage in Barrett’s epithelium compared with healthy squamous epithelium of the oesophagus (28). However, although we compared patients with SCC of the oropharynx to non-tumor patients in an extended case-control study, including matching of gender, age, tobacco and alcohol consumption, we did not find any significant differences in mutagen sensitivity using lymphocytes or mucosa cells. The results demonstrate the importance of matched groups. Moreover, testing of mutagen sensitivity appears to depend on the test system and mutagen used, as well as on the population and cell type to be investigated.
Notably, mutagen sensitivity did not appear to be a risk factor for the development of malignant lesions in our test system. Accordingly, DNA repair was investigated as another possible endogenous marker in head and neck carcinogenesis. The comet assay has been adapted for the detection of DNA repair in lymphocytes (12,29,30). Certain investigations reported differences in DNA repair following stimulation, dependent on the type of DNA damage induced (31,32). Lymphocytes in our study were not stimulated prior to testing, due to recommendations by Mayer et al after the determination of a lack of differences in lymphocytic DRC following PHA-stimulation and γ-irradiation (33). Consequently, the group considered unstimulated mucosa cells from fresh biopsy samples. The use of mucosa cells has previously been described with only minor changes to original lymphocyte protocol (12) and has been published earlier (15,29).
In the present study, lymphocyte DRC15 (p=0.455) and DRC30 (p=0.619) did not differ between cancer patients and patients without malignancy following incubation with NDEA. However, in mucosal cells, DRC15 and DRC30 levels were found to be lower in patients with oropharyngeal tumors vs. controls, although the significance was only observed in DRC30 (Fig. 2B).
The present study demonstrates that DRC of the upper aerodigestive tract target cells is a potential endogenous factor for head and neck cancer susceptibility. However, our data provide evidence that there is no difference in DNA fragility to cigarette smoke-related carcinogens. By contrast, overall DRC appears to be rapidly saturated in HNSCC patients, whereas patients without malignancy are able to continuously increase the proportion of repaired DNA damage with time. The findings of other groups support the role of hereditary reduced DNA repair capacities as risk factors for head and neck cancer (13,34). Additionally, gene polymorphisms in proteins, such as XPD and XRCC1 exert a major role in DNA repair, and thus affect head and neck carcinogenesis (30,35,36). Due to the diverse findings in the cell systems tested in this study, we recommend the use of target tissue cells to investigate DRC in upper aerodigestive tract carcinogenesis. Further studies are likely to focus on the identification of specific chromosomal and genetic alterations in mucosal cells of the upper aerodigestive tract. Previously, a higher sensitivity to tobacco- related carcinogens was determined in chromosomes 3, 5 and 8 in oropharyngeal epithelia of head and neck tumor patients compared to controls (37,38). Further investigation of such data would provide more detailed information on cancer risks and may be the basis for new preventive and therapeutic treatments in head and neck carcinogenesis.
References
- 1.Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. NatRevCancer. 2005;5:127–135. doi: 10.1038/nrc1549. [DOI] [PubMed] [Google Scholar]
- 2.Warnakulasuriya S, Sutherland G, Scully C. Tobacco, oral cancer, and treatment of dependence. Oral Oncol. 2005;41:244–260. doi: 10.1016/j.oraloncology.2004.08.010. [DOI] [PubMed] [Google Scholar]
- 3.Cloos J, Nieuwenhuis EJ, Boomsma DI, Kuik DJ, van der Sterre ML, Arwert F, Snow GB, Braakhuis BJ. Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst. 1999;91:1125–1130. doi: 10.1093/jnci/91.13.1125. [DOI] [PubMed] [Google Scholar]
- 4.IARC. Iarc Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: N′-Nitrosonornicotine (Nnn) IARC; 2007. [Google Scholar]
- 5.Hecht SS. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res. 1999;424:127–142. doi: 10.1016/s0027-5107(99)00014-7. [DOI] [PubMed] [Google Scholar]
- 6.Koppang N, Rivenson A, Dahle HK, Hoffmann D. A study of tobacco carcinogenesis, Liii: carcinogenicity of N′-nitrosonornicotine (Nnn) and 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone (Nnk) in mink (Mustela Vison) Cancer Lett. 1997;111:167–171. doi: 10.1016/s0304-3835(96)04507-7. [DOI] [PubMed] [Google Scholar]
- 7.IARC. Iarc Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: N-Nitrosodiethylamine (Ndea) IARC; 2000. [Google Scholar]
- 8.Weitberg AB, Corvese D. Oxygen radicals potentiate the genetic toxicity of tobacco-specific nitrosamines. Clin Genet. 1993;43:88–91. doi: 10.1111/j.1399-0004.1993.tb04455.x. [DOI] [PubMed] [Google Scholar]
- 9.Compagni A, Christofori G. Recent advances in research on multistage tumorigenesis. Br J Cancer. 2000;83:1–5. doi: 10.1054/bjoc.2000.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science. 1989;246:629–634. doi: 10.1126/science.2683079. [DOI] [PubMed] [Google Scholar]
- 11.Sancar A. Mechanisms of DNA excision repair. Science. 1994;266:1954–1956. doi: 10.1126/science.7801120. [DOI] [PubMed] [Google Scholar]
- 12.Schmezer P, Rajaee-Behbahani N, Risch A, Thiel S, Rittgen W, Drings P, Dienemann H, Kayser KW, Schulz V, Bartsch H. Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagenesis. 2001;16:25–30. doi: 10.1093/mutage/16.1.25. [DOI] [PubMed] [Google Scholar]
- 13.Cheng L, Eicher SA, Guo Z, Hong WK, Spitz MR, Wei Q. Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev. 1998;7:465–468. [PubMed] [Google Scholar]
- 14.Rajaee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Dienemann H, Schulz V, Drings P, Thiel S, Bartsch H. Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int J Cancer. 2001;95:86–91. doi: 10.1002/1097-0215(20010320)95:2<86::aid-ijc1015>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
- 15.Kleinsasser NH, Wallner BC, Kastenbauer ER, Muenzenrieder RK, Harreus UA. Comparing the genotoxic sensitivities of human peripheral blood lymphocytes and mucosa cells of the upper aerodigestive tract using the comet assay. Mutat Res. 2000;467:21–30. doi: 10.1016/s1383-5718(00)00022-x. [DOI] [PubMed] [Google Scholar]
- 16.Harreus U, Schmezer P, Kuchenmeister F, Maier H. Genotoxic effect on human mucous membrane biopsies of the upper aerodigestive tract. Laryngorhinootologie. 1999;78:176–181. [PubMed] [Google Scholar]
- 17.Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184–191. doi: 10.1016/0014-4827(88)90265-0. [DOI] [PubMed] [Google Scholar]
- 18.Olive PL, Durand RE, Le RJ, Olivotto IA, Jackson SM. Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers. Cancer Res. 1993;53:733–736. [PubMed] [Google Scholar]
- 19.Glei M, Habermann N, Osswald K, Seidel C, Persin C, Jahreis G, Pool-Zobel BL. Assessment of DNA damage and its modulation by dietary and genetic factors in smokers using the comet assay: a biomarker model. Biomarkers. 2005;10:203–217. doi: 10.1080/13547500500138963. [DOI] [PubMed] [Google Scholar]
- 20.McKeown SR, Robson T, Price ME, Ho ET, Hirst DG, McKelvey-Martin VJ. Potential use of the alkaline comet assay as a predictor of bladder tumour response to radiation. Br J Cancer. 2003;89:2264–2270. doi: 10.1038/sj.bjc.6601426. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Burlinson B, Tice RR, Speit G, Agurell E, Brendler-Schwaab SY, Collins AR, Escobar P, Honma M, Kumaravel TS, Nakajima M, Sasaki YF, Thybaud V, Uno Y, Vasquez M, Hartmann A. Fourth international workgroup on genotoxicity testing: Results of the in vivo comet assay workgroup. Mutat Res. 2007;627:31–35. doi: 10.1016/j.mrgentox.2006.08.011. [DOI] [PubMed] [Google Scholar]
- 22.Sasiadek M, Schlade-Bartusiak K, Zych M, Noga L, Czemarmazowicz H. Opposite responses in two DNA repair capacity tests in lymphocytes of head and neck cancer patients. J Appl Genet. 2002;43:525–534. [PubMed] [Google Scholar]
- 23.Palyvoda O, Mukalov I, Polanska J, Wygoda A, Drobot L, Widel M, Rzeszowska-Wolny J. Radiation-induced DNA damage and its repair in lymphocytes of patients with head and neck cancer and healthy donors. Anticancer Res. 2002;22:1721–1725. [PubMed] [Google Scholar]
- 24.Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M, Hong WK, Spitz MR. Chromosome instability in lymphocytes: A potential indicator of predisposition to oral premalignant lesions. Cancer Res. 2002;62:2813–2818. [PubMed] [Google Scholar]
- 25.Cloos J, Leemans CR, van der Sterre ML, Kuik DJ, Snow GB, Braakhuis BJ. Mutagen sensitivity as a biomarker for second primary tumors after head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2000;9:713–717. [PubMed] [Google Scholar]
- 26.Schantz SP, Huang Q, Shah K, Murty VV, Hsu TC, Yu G, Andersen PE, Huvos AG, Chaganti RS. Mutagen sensitivity and environmental exposures as contributing causes of chromosome 3p losses in head and neck cancers. Carcinogenesis. 2000;21:1239–1246. [PubMed] [Google Scholar]
- 27.Kleinsasser NH, Wagner C, Wallner BC, Harreus UA, Kastenbauer ER. Mutagen sensitivity of nasopharyngeal cancer patients. Mutat Res. 2001;491:151–161. doi: 10.1016/s1383-5718(01)00137-1. [DOI] [PubMed] [Google Scholar]
- 28.Olliver JR, Hardie LJ, Dexter S, Chalmers D, Wild CP. DNA damage levels are raised in Barrett’s oesophageal mucosa relative to the squamous epithelium of the oesophagus. Biomarkers. 2003;8:509–521. doi: 10.1080/13547500310001644961. [DOI] [PubMed] [Google Scholar]
- 29.Harreus UA, Wallner BC, Kastenbauer ER, Kleinsasser NH. DNA repair if mucous membrane cells and lymphocytes with the comet assay. Laryngorhinootologie. 2001;80:23–26. doi: 10.1055/s-2001-11024. [DOI] [PubMed] [Google Scholar]
- 30.Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev. 2003;12:689–698. [PubMed] [Google Scholar]
- 31.Boerrigter ME, Vijg J. Induction and disappearance of DNA single-strand breaks in human B and T lymphocytes after exposure to ethylnitrosourea. Mutat Res. 1991;255:49–55. doi: 10.1016/0921-8777(91)90017-j. [DOI] [PubMed] [Google Scholar]
- 32.Leroy T, Lison D, Lauwerys R. Preliminary in vitro investigation into the use of alkaline elution assay for the biomonitoring of humans exposed to genotoxic agents. Hum Exp Toxicol. 1995;14:61–68. doi: 10.1177/096032719501400112. [DOI] [PubMed] [Google Scholar]
- 33.Mayer C, Popanda O, Zelezny O, von Brevern MC, Bach A, Bartsch H, Schmezer P. DNA repair capacity after γ-irradiation and expression profiles of DNA repair genes in resting and proliferating human peripheral blood lymphocytes. DNA Repair (Amst) 2002;1:237–250. doi: 10.1016/s1568-7864(01)00019-2. [DOI] [PubMed] [Google Scholar]
- 34.Schantz SP, Zhang ZF, Spitz MS, Sun M, Hsu TC. Genetic susceptibility to head and neck cancer: Interaction between nutrition and mutagen sensitivity. Laryngoscope. 1997;107:765–781. doi: 10.1097/00005537-199706000-00011. [DOI] [PubMed] [Google Scholar]
- 35.Caldecott KW. Xrcc1 and DNA strand break repair. DNA Repair (Amst) 2003;2:955–969. doi: 10.1016/s1568-7864(03)00118-6. [DOI] [PubMed] [Google Scholar]
- 36.Han J, Hankinson SE, Colditz GA, Hunter DJ. Genetic variation in Xrcc1, sun exposure, and risk of skin cancer. Br J Cancer. 2004;91:1604–1609. doi: 10.1038/sj.bjc.6602174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Harreus UA, Kleinsasser NH, Zieger S, Wallner B, Reiter M, Schuller P, Berghaus A. Sensitivity to DNA-damage induction and chromosomal alterations in mucosa cells from patients with and without cancer of the oropharynx detected by a combination of Comet assay and fluorescence in situ hybridization. Mutat Res. 2004;563:131–138. doi: 10.1016/j.mrgentox.2004.06.011. [DOI] [PubMed] [Google Scholar]
- 38.Reiter M, Baumeister P, Zieger S, Harreus U. Chromosomal alterations and mutagen sensitivity in human mucosal cells of the oropharynx and lymphocytes caused by Bpde. Cancer Genomics Proteomics. 2009;6:247–254. [PubMed] [Google Scholar]